GenSci's Ophthalmology Pipeline: IND Approval Secured for Three Indications

Recently, GenSci148 Injection, a VEGF/Ang-2 multispecific fusion protein, has secured clinical trial approval from the National Medical Products Administration (NMPA) for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).

GenSci148 Injection is designed to inhibit multiple signaling pathways by targeting vascular endothelial growth factors (VEGF-A, VEGF-C, VEGF-D) and angiopoietin-2 (Ang-2), thereby suppressing pathological angiogenesis, reducing vascular permeability and improving vascular stability.

nAMD, DME, and RVO are significant contributors to visual impairment and blindness worldwide, representing a substantial and growing disease burden. The existing therapies require repeated intravitreal injections and long-term monitoring, which may affect patient adherence. In addition, some patients may experience suboptimal responses or limited treatment durability.

With its multispecific mechanism and long-acting design, GenSci148 has the potential to improve visual and anatomical outcomes while extending dosing intervals and reducing treatment burden, thereby providing a new option for patients.

Disclosure Notice

1. Innovative drug development entails high risks, and the outcome of clinical trials remains uncertain.

2. This press release is provided as a medical information source for healthcare experts only and is not used for commercial purposes.

3. For diagnosis and treatment information regarding specific medical conditions, please follow the advice and guidance of qualified healthcare professionals.